Prolonged exposition with hyperthermic intraperitoneal chemotherapy (hipec) may provide survival benefit after cytoreductive surgery (crs) in advanced primary epithelial ovarian, fallopian tube, and primary peritoneal cancer

HIGHLIGHTS

• who: Miklos Acs and collaborators from the Department of General and Visceral Surgery, Hospital Barmherzige Bru00fcder, Regensburg, GermanyDivision of Oncology, Department of Internal Medicine and Oncology, Semmelweis University have published the Article: Prolonged Exposition with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) May Provide Survival Benefit after Cytoreductive Surgery (CRS) in Advanced Primary Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer, in the Journal: Cancers 2022, 14, 3301. https:// of 31/05/2022
• what: The authors report the superiority of prolonged application of HIPEC.

SUMMARY

Patients were grouped based on the duration of HIPEC . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.